Toxicity of the Increased Recommended Doses of First-line Anti-tuberculosis Oral Drugs in Children in a Reference Center in Spain

Pereira, Laura; Marco-García, Mónica; Gamell, Anna; Cusó, Teresa; Monsonís, Manuel; Latre, Cristina; Fortuny, Clàudia; Noguera-Julian, Antoni.
Arch. bronconeumol. (Ed. impr.) ; 59(9)sep. 2023. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-225009

Documentos relacionados

  1. Host Bioenergetic Parameters Reveal Cytotoxicity of Antituberculosis Drugs Undetected Using Conventional Viability Assays.
  2. Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents.
  3. In vitro and in vivo local tolerability of a synergistic anti-tuberculosis drug combination intended for pulmonary delivery.
  4. [Influence of phosphogliv® hepatoprotector on phospholipid spectrum of peripheral blood mononuclears in patients with tuberculosis of lungs.]
  5. Acute, subchronic oral toxicity, toxicokinetics, and genotoxicity studies of DFC-2, an antitubercular drug candidate.
  6. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
  7. Indole-fused spirochromenes as potential anti-tubercular agents: design, synthesis and in vitro evaluation.
  8. Effects of a new 1,2,3-thiadiazole containing hydrazone antimycobacterial agent on serum and liver biochemical parameters in female mice.
  9. Neuropsychiatric Effects of Antitubercular Therapy.
  10. Near-infrared molecular sensor for visualizing and tracking ONOO<sup>-</sup> during the process of anti-tuberculosis drug-induced liver damage.